{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.5","upperLimit":"91.3","value":"73.9"},{"groupId":"OG001","lowerLimit":"19.0","upperLimit":"81.0","value":"50.0"},{"groupId":"OG002","lowerLimit":"27.3","upperLimit":"81.7","value":"54.5"},{"groupId":"OG004","lowerLimit":"8.5","upperLimit":"53.1","value":"30.8"},{"groupId":"OG005","lowerLimit":"0.0","upperLimit":"21.1","value":"9.1"},{"groupId":"OG007","lowerLimit":"31.9","upperLimit":"93.1","value":"62.5"},{"groupId":"OG008","lowerLimit":"1.0","upperLimit":"99.0","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"2"}],"units":"Participants"}],"description":"Defined as the time interval from date on treatment until the date of first progression, medulloblastoma-related death or date of last contact for patients who have not experienced an event. Eligible medulloblastoma patients who received any methotrexate and had molecularly confirmed medulloblastoma are included in this analysis. Five patients were excluded as 3 had no archival tissue available and 2 were found to not be medulloblastoma by methylation profile.","dispersionType":"95% Confidence Interval","groups":[{"description":"Sonic hedgehog (SHH) medulloblastoma subgroup patients in the low-risk group","id":"OG000","title":"Low-risk SHH Patients"},{"description":"Sonic hedgehog (SHH) medulloblastoma subgroup patients in the intermediate-risk group","id":"OG001","title":"Intermediate-risk SHH Patients"},{"description":"Sonic hedgehog (SHH) medulloblastoma subgroup patients in the high-risk group","id":"OG002","title":"High-risk SHH Patients"},{"description":"Group 3 (G3) medulloblastoma subgroup patients in the low-risk group","id":"OG003","title":"Low-risk Group 3 Patients"},{"description":"Group 3 medulloblastoma subgroup patients in the intermediate-risk group","id":"OG004","title":"Intermediate-risk Group 3 Patients"},{"description":"Group 3 medulloblastoma subgroup patients in the high-risk group","id":"OG005","title":"High-risk Group 3 Patients"},{"description":"Group 4 (G4) medulloblastoma subgroup patients in the low-risk group","id":"OG006","title":"Low-risk Group 4 Patients"},{"description":"Group 4 (G4) medulloblastoma subgroup patients in the intermediate-risk group","id":"OG007","title":"Intermediate-risk Group 4 Patients"},{"description":"Group 4 medulloblastoma subgroup patients in the high-risk group","id":"OG008","title":"High-risk Group 4 Patients"}],"paramType":"NUMBER","populationDescription":"Eligible patients with molecularly confirmed medulloblastoma (n=76) were included. PFS estimates are reported by methylation subgroup and risk group. There were no low-risk group 3 or group 4 patients.","reportingStatus":"POSTED","timeFrame":"From date on treatment to date of first progression or relapse or disease related death or date of last contact, estimated at 1 year after treatment","title":"Percent Probability of Progression-free Survival (PFS) for Medulloblastoma Patients by DNA Methylation Subgroup","type":"PRIMARY","unitOfMeasure":"Percent Probability"}